Abstract: The agent for inhibiting inflammation promoted by GM3 of the present invention comprises a substance that inhibits inflammation promoted by GM3 as an active ingredient. The substance which inhibits inflammation promoted by GM3 is preferably a ganglioside having 2 or more of sialic acids. The ganglioside having 2 or more of sialic acids is at least one kind of ganglioside selected from the group consisting of GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c, and GP1c. Further, the substance which inhibits inflammation promoted by GM3 has a structure represented by the following formula (1): [In the formula (1), R1 represents a glycan constituting ganglioside GM3, R2—C(?O)— represents a fatty acid residue having 18 or less of carbon atoms, or an unsaturated fatty acid residue having 20 or more of carbon atoms.

Abstract: The present invention is a method for detecting at least one disease selected from the group consisting of visceral fat accumulation, hyperglycemia, dyslipidemia, hypertension and atherosclerosis or a disease two or more of which are combined or detecting onset risk of these diseases, which comprises (a) a step of measuring a ganglioside GM3 in a blood sample derived from a subject, wherein the ganglioside GM3 has a structure represented by the following formula (1). [In the formula (1), R1 represents a glycan constituting the ganglioside GM3, and R2—C(?O)— represents a fatty acid residue having 16 or more and 24 or less carbon atoms which may have a double bond, and having an OH group as a substituent.

Abstract: The agent for inhibiting inflammation promoted by GM3 of the present invention comprises a substance that inhibits inflammation promoted by GM3 as an active ingredient. The substance which inhibits inflammation promoted by GM3 is preferably a ganglioside having 2 or more of sialic acids. The ganglioside having 2 or more of sialic acids is at least one kind of ganglioside selected from the group consisting of GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c, and GP1c. Further, the substance which inhibits inflammation promoted by GM3 has a structure represented by the following formula (1): [In the formula (1), R1 represents a glycan constituting ganglioside GM3, R2—C(?O)— represents a fatty acid residue having 18 or less of carbon atoms, or an unsaturated fatty acid residue having 20 or more of carbon atoms.

Abstract: The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.

Abstract: The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.

Abstract: A method for directly inhibiting proliferation of Helicobacter pylori bacteria, that includes administering to a subject infected with Helicobacter pylori an N-acetylglucosaminyl beta-linked monosaccharide represented by: GlcNAcl-beta-O—Y where Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group, or an alkoxycarbonyl group.

Abstract: It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.

Abstract: The problem is to provide a MALDI mass spectrometry method that can be used for a mass spectrometry method by a general MALDI method with which it is possible to measure multiple molecules to be measured that are contained in a sample quantitatively in a short period of time with good efficiency compared with conventional methods. The problem is solved by a MALDI mass spectrometry method for a sample containing multiple molecules to be measured, which is a MALDI mass spectrometry method characterized in that the multiple molecules to be measured are a saccharide mixture, a glycopeptide mixture, a glycopeptide-peptide mixture, a glycoprotein mixture, or a glycoprotein-protein mixture, and that a quantitative mass spectrum of the multiple molecules to be measured is obtained from an arbitrary point in the sample to be measured where a signal is detected without measuring and integrated averaging the entire sample to be measured.

Abstract: The present invention provides a method for obtaining structural information conveniently and rapidly by generating a negative ion without adding an acidic substance to matrix, thereby improving sensitivity of measurement by a mass spectrometer, and by generating structural specific ions with high reproducibility, and a method for screening disease marker and a method for analyzing a sample containing a biomolecule. A method for mass spectrometry of a sugar chain comprising the steps of: preparing a sample containing a sugar chain; labeling the sugar chain with a labeling compound, to obtain a labeled sugar chain; and subjecting the labeled sugar chain to measurement of negative ions by using a MALDI mass spectrometer, thereby conducting analysis of the sugar chain.

Abstract: A method for inhibiting proliferation of Helicobacter pylori including a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) GlcNAc1-alpha-O—Y ??(1) (in the formula (1), Y is a straight-, branched- or cyclic-aliphatic hydrocarbon group having 1 to 27 carbon atoms or a straight-, branched- or cyclic-acyl group having 1 to 27 carbon atoms). The diet of the food, the beverage or the pharmaceutical preparation comprises the proliferation inhibitor of Helicobacter pylori.

Abstract: A method for directly inhibiting proliferation of Helicobacter pylori bacteria, that includes administering to a subject infected with Helicobacter pylori an N-acetylglucosaminyl beta-linked monosaccharide represented by: GlcNAcl-beta-O—Y where Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group, or an alkoxycarbonyl group.

Abstract: It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.

Abstract: The present invention provides a method for accurately discriminating between prostate carcinoma and benign prostatic hyperplasia based on a glycan structure of prostate specific antigen (PSA). The method of the present invention includes the steps of: purifying PSA from a sample derived from a subject; preparing a PSA derivative from the PSA; labeling the PSA derivative; and analyzing the labeled PSA derivative by the mass spectrometry method, in which the subject is identified as having prostate carcinoma when the ratio of the signal intensity of fucose-unbound glycan to the signal intensity of fucose-bound glycan in the labeled PSA derivative is greater than 1.0, and identified as having benign prostatic hyperplasia when the ratio is 1.0 or less.

Abstract: The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(?)).

Abstract: A proliferation inhibitor of H. pylori bacteria comprising a compound that can specifically inhibit the proliferation of H. pylori bacteria, which does not generate bacterium resistant, can be eaten, drunken or administrated safely for a long period of time, can be simply mass-manufactured and can be used for foods and beverages or pharmaceutical preparation. The proliferation inhibitor of H. pylori bacteria comprises an N-acetylglucosaminyl beta-linked monosaccharide derivative represented by the following chemical formula (1): GlcNAc1-beta-O—Y??(1) wherein Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group or an alkoxycarbonyl group.

Abstract: An object of the invention is to provide a method for enabling MSn (n>) analysis of a trace amount of a sample and easily and rapidly obtaining structural information by identifying a bonding position of the labeling compound in a molecule with the MSn (n>) analysis. According to the present invention, by labeling a particular moiety of the molecule in a stable manner, ions are easily generated and stabilized, thereby improving sensitivity of the MS. The amount of precursor ions generated in this manner is an amount enough to carry out the MSn (n>1) analysis and to generate structure-specific ions with high reproducibility. The structural information can be easily and rapidly obtained with high sensitivity.

Abstract: A mesoporous catalyst for purifying lean burn NOx emission including a mesoporous material, which substantially has pores with a diameter of 2 to 50 nm and a specific surface area of 100 to 1,400 m2/g, selected from the group consisting of mesoporous silica and mesoporous alumina, and 0.01 to 20 mass % of a catalyst carried on the mesoporous material with an average particle size of 1 to 20 nm containing platinum and/or iridium is provided.

Abstract: A method for inhibiting proliferation of Helicobacter pylori including a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) GlcNAc1-alpha-O—Y ??(1) (in the formula (1), Y is a straight-, branched- or cyclic-aliphatic hydrocarbon group having 1 to 27 carbon atoms or a straight-, branched- or cyclic-acyl group having 1 to 27 carbon atoms). The diet of the food, the beverage or the pharmaceutical preparation comprises the proliferation inhibitor of Helicobacter pylori.

Abstract: The present invention provides a method for obtaining structural information conveniently and rapidly by generating a negative ion without adding an acidic substance to matrix, thereby improving sensitivity of measurement by a mass spectrometer, and by generating structural specific ions with high reproducibility, and a method for screening disease marker and a method for analyzing a sample containing a biomolecule. A method for mass spectrometry of a sugar chain comprising the steps of: preparing a sample containing a sugar chain; labeling the sugar chain with a labeling compound, to obtain a labeled sugar chain; and subjecting the labeled sugar chain to measurement of negative ions by using a MALDI mass spectrometer, thereby conducting analysis of the sugar chain.

Abstract: The present invention herein provides a proliferation inhibitor of Helicobacter pylori comprising a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) GlcNAc1-alpha-O-Y ??(1) (in the formula (1), Y is a straight-, branched- or cyclic-aliphatic hydrocarbon group having 1 to 27 carbon atoms or a straight-, branched- or cyclic-acyl group having 1 to 27 carbon atoms). The diet of the food, the beverage or the pharmaceutical preparation comprises the proliferation inhibitor of Helicobacter pylori.